Literature DB >> 14665805

Dosage regimes in the prescription of heroin and other narcotics to chronic opioid addicts in Switzerland--Swiss national cohort study.

Patrick Gschwend1, Jürgen Rehm, Richard Blättler, Thomas Steffen, André Seidenberg, Stephan Christen, Christoph Bürki, Felix Gutzwiller.   

Abstract

AIMS: Within the guidelines of the research programme on medical prescription of narcotics for opioid addicts (PROVE), heroin, morphine, and methadone were prescribed to heavily opioid addicted individuals in Switzerland since 1994. This contribution analyses the course of dose levels during the treatment period.
DESIGN: Naturalistic description of consumed dosages per day and month. SETTING AND PARTICIPANTS: The study describes the dosages prescribed to all individuals who began outpatient treatment in the PROVE programme in Switzerland between 1994 and 1996. MEASUREMENTS: Consumed amount of narcotics per day and the course of dosage of injectable heroin in different treatment regimes.
FINDINGS: Heroin was the most frequently prescribed narcotic. Of all consumption days, heroin had been applied in 77% as injection and in 9% in a smokeable form. The mean daily dosage was 474 mg for intravenous application and 993 mg for the smokeable form. Second most frequent was the prescription of oral methadone, in most cases in combination with heroin. The mean amount of daily consumption of oral methadone was 53 mg. There were dosage differences between treatment regimes. During the course of treatment the mean dosage for injectable heroin per day decreased significantly and, depending on the treatment regime, almost linearly.
CONCLUSIONS: The significance of heroin dosages in heroin-assisted therapy for treatment outcome should be further explored, especially in the light of the markedly higher dosages in Switzerland compared to the UK. During the treatment period, dosages did not increase but generally decreased, indicating no further increase in tolerance. Copyright 2004 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14665805     DOI: 10.1159/000073725

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  6 in total

1.  Cross-reactivity of the CEDIA buprenorphine assay with opiates: an Austrian phenomenon?

Authors:  M Pavlic; K Libiseller; P Grubwieser; W Rabl
Journal:  Int J Legal Med       Date:  2005-04-16       Impact factor: 2.686

Review 2.  Immunosuppressive effects of opioids--clinical relevance.

Authors:  Alexander Brack; Heike L Rittner; Christoph Stein
Journal:  J Neuroimmune Pharmacol       Date:  2011-07-05       Impact factor: 4.147

3.  Development and validation of a solid-phase extraction gas chromatography-mass spectrometry method for the simultaneous quantification of methadone, heroin, cocaine and metabolites in sweat.

Authors:  Bertrand R Brunet; Allan J Barnes; Karl B Scheidweiler; Patrick Mura; Marilyn A Huestis
Journal:  Anal Bioanal Chem       Date:  2008-07-08       Impact factor: 4.142

Review 4.  Prescription of heroin for the management of heroin dependence: current status.

Authors:  Nicholas Lintzeris
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

5.  Behavioral economic analysis of opioid consumption in heroin-dependent individuals: effects of alternative reinforcer magnitude and post-session drug supply.

Authors:  Mark K Greenwald; Caren L Steinmiller
Journal:  Drug Alcohol Depend       Date:  2009-05-21       Impact factor: 4.492

6.  Effects of cortisol administration on craving in heroin addicts.

Authors:  M Walter; D Bentz; N Schicktanz; A Milnik; A Aerni; C Gerhards; K Schwegler; M Vogel; J Blum; O Schmid; B Roozendaal; U E Lang; S Borgwardt; D de Quervain
Journal:  Transl Psychiatry       Date:  2015-07-28       Impact factor: 6.222

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.